Phase 2 clinical trial of Imprime PGG and bevacizumab achieved meaningful reductions in tumour burden
15 April 2015 | By Victoria White
The Phase 2 clinical trial of Imprime PGG and bevacizumab achieved meaningful reductions in tumour burden in patients with non-small cell lung cancer...

































